In a landmark move, Texas Attorney General Ken Paxton is suing Johnson & Johnson and Kenvue, the companies behind Tylenol, for allegedly misleading pregnant mothers about the pain reliever’s safety. The lawsuit centers on unproven claims associating early acetaminophen exposure with autism, sparking a critical discussion on consumer protection, corporate liability, and scientific integrity.
The state of Texas has escalated a long-simmering debate surrounding the safety of acetaminophen, the active ingredient in popular pain relievers like Tylenol, for pregnant women. On Tuesday, Texas Attorney General Ken Paxton filed a lawsuit accusing pharmaceutical giants Johnson & Johnson and its spin-off, Kenvue, of deceptively marketing Tylenol to expectant mothers, asserting unproven links between early exposure to the drug and an increased risk of autism and other disorders. This legal action comes weeks after similar unproven claims were voiced by high-profile figures, including President Donald Trump and Health Secretary Robert F. Kennedy Jr., highlighting a growing public discourse on the complex brain disorder.
The Core Allegations: Deceptive Marketing and Liability Transfers
The lawsuit brought by Attorney General Paxton in a state court in rural Panola County is multifaceted, presenting several serious accusations against the companies. Specifically, it alleges that:
- The companies violated Texas consumer protection laws by concealing potential dangers that acetaminophen posed to fetuses and young children.
- Tylenol was “deceptively marketed… as the only safe painkiller for pregnant women,” potentially misleading millions of consumers.
- Johnson & Johnson fraudulently transferred liabilities related to Tylenol to Kenvue in an attempt to safeguard its assets against impending lawsuits.
This last allegation points to J&J’s 2021 decision to spin off its consumer health business, including Tylenol, into a separate entity now known as Kenvue. Paxton stated, “Big Pharma betrayed America by profiting off of pain and pushing pills regardless of the risks. These corporations lied for decades, knowingly endangering millions to line their pockets.” He further criticized Johnson & Johnson for allegedly attempting “to escape responsibility by illegally offloading their liability onto a different company” as a “day of reckoning was coming,” as reported by The Associated Press.
Kenvue’s Firm Defense and Medical Consensus
In response to the lawsuit, Kenvue, the Summit, New Jersey-based company now owning Tylenol’s rights and liabilities, has vehemently denied the claims. The company stressed that acetaminophen remains the safest pain reliever option for pregnant women. Kenvue highlighted that untreated high fevers and pain during pregnancy are recognized risks to both mothers and fetuses. “We stand firmly with the global medical community that acknowledges the safety of acetaminophen and believe we will continue to be successful in litigation as these claims lack legal merit and scientific support,” Kenvue asserted in a statement, expressing concern over the “perpetuation of misinformation” about the drug’s safety and its potential impact on the health of women and children, according to The Associated Press.
This position aligns with the consensus of many leading medical organizations. For instance, the Centers for Disease Control and Prevention (CDC) provides information on autism spectrum disorder (ASD) and its risk factors, generally pointing to a combination of genetic and environmental factors, without identifying acetaminophen as a proven cause. While some studies have explored a potential association between prenatal acetaminophen use and neurodevelopmental outcomes, the broader scientific and medical community has not established a definitive causal link to autism, as many other studies have found no connection. The importance of consulting healthcare providers for guidance on medication during pregnancy is consistently emphasized by health experts. For additional context on autism risk factors, readers can refer to official health resources such as the CDC’s information on Autism Spectrum Disorder.
The Broader Context: Public Health and Corporate Accountability
The Texas lawsuit is not an isolated incident. Kenvue has already acknowledged facing similar litigation in federal court concerning autism claims. Earlier this year, in an annual filing, the company noted that while many of those claims have been dismissed, they are currently under appeal. The legal challenges reflect a broader public concern regarding pharmaceutical safety and the extent of corporate responsibility in marketing medications, especially to vulnerable populations like pregnant women.
With acetaminophen being one of the most widely used pain relievers in the U.S., taken by over 100 million Americans annually, the implications of this lawsuit are significant. Texas is seeking a jury trial and is asking the court to order the companies to pay the state $10,000 for each violation of the Deceptive Trade Practices-Consumer Protection Act. Furthermore, the state demands that the companies destroy marketing materials that claim Tylenol is safe for pregnant women and children or deny that it causes autism or Attention-Deficit/Hyperactivity Disorder (ADHD) in children exposed to the drug prenatally or in early childhood.
This case underscores the ongoing tension between public health information, pharmaceutical marketing, and consumer protection. It highlights the critical need for clear, evidence-based communication about medication safety, especially when claims, proven or unproven, could influence health decisions for millions of families.
